文献速递产科母胎医学

无线远程居家胎心与母心监测方案

Wireless, remote solution for home fetal and maternal heart rate monitoring.
PubMed 文献 · Am J Obstet Gynecol MFM · 2020-03-17

这项前瞻性、开放标签、多中心研究纳入147例≥32+0周单胎孕妇,同步比较Invu无线可穿戴自戴设备与胎心监护仪(CTG)的胎心率和母心率监测。Invu与CTG胎心率高度相关(r=0.92,P<0.0001),95%一致性界限为-8.84至8.24 bpm;母心率也高度相关(r=0.97,P<0.0001),研究期间无不良事件报告。

要点

  • Invu无线设备与CTG胎心率高度相关(r=0.92),一致性界限在临床可接受范围内。
  • Invu母心率与CTG高度相关(r=0.97),支持同步母胎监测。
  • 设备采用被动传感技术,支持诊所及远程自戴监测,研究期间无不良事件。

核心结论

  • Invu系统通过被动方法无线获得的胎心率和母心率与当前标准CTG监测结果非常相似。
  • Invu胎心率与CTG的一致性界限在临床可接受的±8 bpm范围内。
  • Invu设备使用被动技术,可在诊所和远程实现安全、无创、便捷的监测。

研究设计与样本

  • 前瞻性、开放标签、多中心研究(NCT03504189),评估Invu与CTG在孕妇中的同步使用。
  • 纳入18至50岁、单胎妊娠≥32+0周孕妇,最终147例纳入分析。
  • Invu与CTG同步记录时长≥30分钟,Invu的8个电传感器和4个声传感器数据无线传输至云端算法分析。

主要发现

  • 孕妇平均(SD)年龄31.8±6.9岁,平均孕周37.7±2.3周。
  • Invu与CTG胎心率测量高度显著相关(r=0.92;P<0.0001)。
  • 胎心率差值的95%一致性界限为-8.84 bpm至8.24 bpm。
  • Invu母心率与CTG高度显著相关(r=0.97;P<0.0001)。
  • 研究期间未报告不良事件。

关键数值与推荐

  • 主要性能终点为Invu胎心率与CTG胎心率的一致性界限在±10 bpm以内。

临床怎么用

  • Invu可作为无线、可穿戴、自戴的胎心率和母心率监测工具,用于诊所及远程场景。
  • 被动传感技术避免主动发射,支持安全、无创、便捷的母胎监测。
  • 远程围产监测有望缓解产前检查可及性障碍及多次就诊负担。

局限性

  • 需进一步研究远程围产监测如何最好地应对产前保健及母胎结局方面的挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Access to prenatal care can be challenging due to physician shortages and rural geography. The multiple prenatal visits performed to collect basic fetal measurements lead to significant patient burden as well. The standard of care tools for fetal monitoring, external fetal heart rate monitoring with cardiotocography, as used today, must be applied by a medical professional in a healthcare setting. Novel tools to enable a remote and self-administered fetal monitoring solution would significantly alleviate some of the current barriers to care. OBJECTIVE: To compare maternal and fetal heart rate monitoring data obtained by 'Invu system' (a wireless, wearable, self-administered, fixed-location device containing passive electrical and acoustic sensors) to cardiotocography, toward a true remote fetal monitoring solution. MATERIALS AND METHODS: A prospective, open-label, multicenter study evaluated concurrent use of Invu and cardiotocography in pregnant women, aged 18 to 50 years, with singleton pregnancies ≥32+0 weeks' gestation (NCT03504189). Simultaneous recording sessions from Invu and cardiotocography lasted for ≥30 minutes. Data from the 8 electrical sensors and 4 acoustic sensors in the Invu belt were acquired, digitized, and sent wirelessly for analysis by an algorithm on cloud-based servers. The algorithm validates the data, preprocesses the data to remove noise, detects heartbeats independently from the two data sources (electrical and acoustic), and fuses the detected heartbeat arrays to calculate fetal heart rate (FHR) and maternal heart rate (MHR). The primary performance endpoint was Invu FHR limit of agreement within ± 10 beats per minute (bpm) of FHR measured with cardiotocography. RESULTS: A total of 147 women were included in the study analysis. The mean (SD) maternal age was 31.8 ±6.9 years, and the mean gestational age was 37.7 ±2.3 weeks. There was a highly significant correlation between FHR measurements from Invu and cardiotocography (r = 0.92; P<0.0001). The 95% limits of agreement for the difference, the range within which most differences between the two measurements will lie, were -8.84 bpm to 8.24 bpm. Invu measurements of MHR were also very similar to cardiotocography and were highly significantly correlated (r = 0.97; P<0.0001). No adverse events were reported during the study. CONCLUSION: Although captured by very different methods, the FHR and MHR outputs wirelessly obtained by the Invu system through passive methods were very similar to those obtained by the current standard of care. The limits of agreement for FHR measured by Invu were within a clinically acceptable ± 8 bpm of cardiotocography FHR. The Invu device uses passive technology to allow for safe, non-invasive and convenient monitoring of patients in the clinic and remotely. Further work should investigate how remote perinatal monitoring could best address some of the recent challenges seen with prenatal care and maternal and fetal outcomes. CLINICAL TRIAL INFORMATION: Registration date: April 20, 2018; First participant enrollment: February 28, 2018; ClinicalTrials.gov registration NCT03504189; https://clinicaltrials.gov/ct2/show/NCT03504189.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Mhajna M, Schwartz N, Levit-Rosen L, et al. Wireless, remote solution for home fetal and maternal heart rate monitoring. Am J Obstet Gynecol MFM. 2020. PMID: 33345967. doi:10.1016/j.ajogmf.2020.100101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。